Ted M Burns

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10529370/publications.pdf

Version: 2024-02-01

79 papers	4,297 citations	136950 32 h-index	114465 63 g-index
81 all docs	81 docs citations	81 times ranked	2833 citing authors

#	Article	IF	Citations
1	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
2	Myasthenia gravis. Nature Reviews Disease Primers, 2019, 5, 30.	30.5	421
3	The MG Composite. Neurology, 2010, 74, 1434-1440.	1.1	195
4	Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology, 2017, 89, 1069-1077.	1.1	185
5	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 2019, 92, e2661-e2673.	1.1	169
6	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
7	Less is more, or almost as much: A 15â€item qualityâ€ofâ€life instrument for myasthenia gravis. Muscle and Nerve, 2008, 38, 957-963.	2.2	149
8	An update on the classification and treatment of vasculitic neuropathy. Lancet Neurology, The, 2005, 4, 853-865.	10.2	136
9	Electrical impedance myography as a biomarker to assess ALS progression. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 439-445.	2.1	125
10	Recommendations for myasthenia gravis clinical trials. Muscle and Nerve, 2012, 45, 909-917.	2.2	122
11	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology, 2020, 95, e59-e69.	1.1	119
12	Mycophenolate mofetil in AChRâ€antibodyâ€positive myasthenia gravis: Outcomes in 102 patients. Muscle and Nerve, 2010, 41, 593-598.	2.2	109
13	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
14	Construction of an efficient evaluative instrument for Myasthenia Gravis: The MG composite. Muscle and Nerve, 2008, 38, 1553-1562.	2.2	105
15	MGâ€ADL: Still a relevant outcome measure. Muscle and Nerve, 2011, 44, 727-731.	2.2	96
16	Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle and Nerve, 2012, 46, 9-25.	2.2	96
17	Guillain-BarrÃ© Syndrome. Seminars in Neurology, 2008, 28, 152-167.	1.4	93
18	Neurosarcoidosis. Archives of Neurology, 2003, 60, 1166.	4.5	89

#	Article	IF	Citations
19	The MGâ€QOL15 for following the healthâ€related quality of life of patients with myasthenia gravis. Muscle and Nerve, 2011, 43, 14-18.	2.2	86
20	International clinimetric evaluation of the MGâ€QOL15, resulting in slight revision and subsequent validation of the MGâ€QOL15r. Muscle and Nerve, 2016, 54, 1015-1022.	2.2	85
21	Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?. Muscle and Nerve, 2014, 49, 483-486.	2.2	73
22	Construct and concurrent validation of the MGâ€QOL15 in the practice setting. Muscle and Nerve, 2010, 41, 219-226.	2.2	69
23	Oculobulbar involvement is typical with Lambert-Eaton Myasthenic Syndrome. Annals of Neurology, 2003, 53, 270-273.	5.3	62
24	Electrical impedance myography correlates with standard measures of Als severity. Muscle and Nerve, 2014, 49, 441-443.	2.2	61
25	Adynamic ileus in severe Guillain-BarrÃ© syndrome. Muscle and Nerve, 2001, 24, 963-965.	2.2	59
26	Crossâ€sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. Muscle and Nerve, 2019, 60, 707-715.	2.2	56
27	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle and Nerve, 2019, 59, 404-410.	2.2	56
28	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
29	History of outcome measures for myasthenia gravis. Muscle and Nerve, 2010, 42, 5-13.	2.2	48
30	Vasculitic Neuropathies. Neurologic Clinics, 2007, 25, 89-113.	1.8	45
31	Neuroleukemiosis: Case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle and Nerve, 2008, 38, 1196-1200.	2.2	43
32	Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology, 1999, 52, 1490-1490.	1.1	35
33	Myasthenia Gravis. Seminars in Neurology, 2015, 35, 327-339.	1.4	34
34	The Evaluation of Polyneuropathies. Neurology, 2011, 76, S6-13.	1.1	32
35	Clinical versus quantitative vibration assessment: improving clinical performance. Journal of the Peripheral Nervous System, 2002, 7, 112-117.	3.1	26
36	The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Annals of the New York Academy of Sciences, 2012, 1274, 99-106.	3.8	26

#	Article	IF	Citations
37	Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. Muscle and Nerve, 2015, 52, 211-215.	2.2	24
38	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
39	Gasoline sniffing multifocal neuropathy. Pediatric Neurology, 2001, 25, 419-421.	2.1	19
40	Clinical applications of therapeutic apheresis. Journal of Clinical Apheresis, 2010, 25, 250-264.	1.3	19
41	The forecast for podcasts: Sunny skies but not necessarily with clear visibility. Neurology, 2007, 68, E19-E20.	1.1	18
42	Psychometric evaluation of the myasthenia gravis composite using rasch analysis. Muscle and Nerve, 2012, 45, 820-825.	2.2	18
43	The modified rankin scale to assess disability in myasthenia gravis: Comparing with other tools. Muscle and Nerve, 2014, 50, 501-507.	2.2	18
44	Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states. Muscle and Nerve, 2015, 51, 635-637.	2.2	18
45	Novel myelin protein zero mutation (Arg36Trp) in a patient with acute onset painful neuropathy. Neuromuscular Disorders, 2006, 16, 308-310.	0.6	17
46	Brazilian cross-cultural translation and adaptation of the "Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items". Arquivos De Neuro-Psiquiatria, 2013, 71, 955-958.	0.8	17
47	Construction and validation of the chronic acquired polyneuropathy patientâ€reported index (CAPâ€PRI): A diseaseâ€specific, healthâ€related qualityâ€ofâ€life instrument. Muscle and Nerve, 2016, 54, 9-17.	2.2	17
48	Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). Journal of Allergy and Clinical Immunology, 2017, 139, 2007-2010.e8.	2.9	17
49	Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Archives of Neurology, 2004, 61, 973.	4.5	16
50	Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders. Mayo Clinic Proceedings, 2003, 78, 858-868.	3.0	15
51	Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology, 2005, 64, 399-400.	1.1	13
52	The Evaluation of Chronic Axonal Polyneuropathies. Seminars in Neurology, 2008, 28, 133-151.	1.4	13
53	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	6.9	13
54	The best of both worlds: Using patientâ€reported plus physicianâ€scored measures during the evaluation of myasthenia gravis. Muscle and Nerve, 2016, 53, 3-4.	2.2	12

#	Article	IF	Citations
55	The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients. Muscle and Nerve, 2011, 43, 329-334.	2.2	11
56	Pearls and Oy-sters: Evaluation of peripheral neuropathies. Neurology, 2009, 72, e28-31.	1.1	10
57	A step forward for stiff-person syndrome. Lancet, The, 2005, 365, 1365-1367.	13.7	9
58	Quality of life measures for myasthenia gravis and evaluation of nonâ€motor symptoms. Clinical and Experimental Neuroimmunology, 2015, 6, 32-39.	1.0	9
59	SUNCT headaches after ipsilateral ophthalmic-distribution zoster. Journal of the Neurological Sciences, 2016, 366, 207-208.	0.6	8
60	Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. Muscle and Nerve, 2019, 60, 161-168.	2.2	8
61	A crisis in <scp>US</scp> drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 1. Muscle and Nerve, 2020, 62, 567-572.	2.2	7
62	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology, 2018, 90, e2034-e2041.	1.1	6
63	Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 247-252.	3.1	5
64	A crisis in <scp>US</scp> drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2. Muscle and Nerve, 2020, 62, 573-578.	2.2	5
65	Clinical outcome assessments: The â€œRaschâ€onaleâ€for improved accuracy. Muscle and Nerve, 2018, 58, 327-329.	2.2	4
66	The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. PLoS ONE, 2022, 17, e0262109.	2.5	3
67	More than meets the eye: The benefits of listening closely to what our patients with myasthenia gravis are telling us. Muscle and Nerve, 2012, 46, 153-154.	2.2	1
68	Reply. Muscle and Nerve, 2013, 47, 145-146.	2.2	1
69	Using disease-specific, patient-reported measures in everyday clinic. Neurology, 2016, 87, 858-859.	1.1	1
70	Reply. Muscle and Nerve, 2017, 55, 138-140.	2.2	1
71	On being sick. Neurology, 2017, 89, 414-416.	1.1	1
72	Adynamic ileus in severe Guillainâ€“BarrÃ© syndrome. Muscle and Nerve, 2001, 24, 963-965.	2.2	1

#	Article	IF	Citations
73	Peripheral Neuropathies in Infants and Children: Polyneuropathies, Mononeuropathies, Plexopathies, and Radiculopathies. , 2005, , 2707-2753.		0
74	Clinical Neurophysiology of Pediatric Polyneuropathies. , 2006, , 645-686.		0
75	Neuromuscular Disorders. Seminars in Neurology, 2008, 28, 131-132.	1.4	0
76	Case of the month: Leukemic nerve infiltration. Muscle and Nerve, 2009, 39, 413-414.	2.2	0
77	Estimating and managing fatigue for our patients: Are we measuring up?. Muscle and Nerve, 2018, 58, 182-183.	2.2	0
78	Autonomic Testing in Childhood. , 2006, , 687-712.		0
79	Rising Drug Costs for Neurologic Diseases. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1392-1406.	0.8	0